The emergence of KRAS-G12C inhibitors represents a significant breakthrough in NSCLC treatment, yet their clinical efficacy remains constrained by primary and acquired resistance mechanisms [9, 10, 12]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.